Objective Europe is greying. This has enormous economic and social costs for the entire society, through greater numbers of healthy older adults with cognitive decline, and of people with neurodegenerative disorders that can lead to dementia, such as Parkinson’s disease (PD). MOTIVAGEING aims to address this issue by proposing a new approach for the enhancement of working memory (WM) capacity, in order to improve cognitive function, quality of life and wellbeing of healthy older adults and PD patients. In fact, there is no current effective treatment for age-related WM decline or WM deficits and related behavioural and affective problems in PD patients. Based on a promising new theory of cognitive neuroscience, the Motivation-Cognition Interaction (MoCoInt) framework, the present plan employs an interdisciplinary approach: in Study 1, an innovative multimodal functional neuroimaging method is proposed to analyse for the first time the neural mechanisms of MoCoInt in healthy ageing. The new evidence will provide a foundation for Study 2, in which the efficacy of a novel WM training procedure, based on MoCoInt, will be tested in healthy older adults in order to improve their WM capacity. Finally, to understand if this new training procedure can be employed to treat WM deficits in PD, Study 3 investigates for the first time MoCoInt mechanisms in PD patients in relation to pharmacological treatment, through the conduct of a randomised controlled drug trial. Results will enable to extend MoCoInt to healthy and pathological ageing, and to develop a new framework that will be available as a new theoretical model for both researchers and clinicians. MOTIVAGEING will therefore have both a significant scientific multidisciplinary impact, filling several gaps in knowledge in cognitive neuroscience, cognitive and clinical neuropsychology, and a valuable social and economic impact in the European Union, helping to address the crucial issues posed by the ageing population. Fields of science natural sciencesbiological sciencesneurobiologycognitive neurosciencemedical and health sciencesbasic medicineneurologyparkinson Keywords Motivation Ageing Parkinson’s disease Working memory dopamine reward fMRI PET drug trials non-invasive brain stimulation cognitive training Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Topic(s) MSCA-IF-2016 - Individual Fellowships Call for proposal H2020-MSCA-IF-2016 See other projects for this call Funding Scheme MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF) Coordinator UNIVERSITY OF KEELE ROYAL CHARTER Net EU contribution € 251 857,80 Address Keele university finance dpt ST5 5BG Keele United Kingdom See on map Region West Midlands (England) Shropshire and Staffordshire Staffordshire CC Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. THE WASHINGTON UNIVERSITY CORPORATION United States Net EU contribution € 0,00 Address Office of sponsored research services -one brookings drive MO 63130-4899 St louis See on map Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 160 130,40
